Table 1.
Culture Substrate | Cell Type | Highlighted Results | Reference |
---|---|---|---|
| |||
Xenogenic Feeder Cells | |||
| |||
MEF feeders | ICM of blastocyst (derived lines H1, H7, H9, H13, H14) | Continuously cultured and remained undifferentiated for over 8 months | [7] |
MEF feeders | iPSC | Remained undifferentiated and proliferated for at least 4 months | [29] |
MEF feeders | hESC (derived HES-1, HES-2) | Sustained culture for up to 64 passages | [5] |
Mouse fetal liver feeders (AFT024) | CD34+ UC-HSPC | More efficient engraftment in mice than human BM stromal cell monolayers | [41] |
PMVEC | CD34+ UC-HSPC | 470 fold increase in CD34+ CD38− population compared to stroma-free culture | [40] |
| |||
Human Feeder Cells | |||
| |||
Human Oviductal epithelial feeders | ICM of blastocyst | All cells differentiate after second sub-culture | [27] |
Human AFT epithelial feeders | hESC (HES-3, HES-4) | Self-renewal maintained for at least 20 passages | [43] |
| |||
Culture Substrate | Cell Type | Highlighted Results | Reference |
| |||
Human FM feeders | hESC (HES-3, HES-4) | Self-renewal maintained for at least 20 passages | [43] |
Human FS feeders | hESC (HES-3, HES-4) | Self-renewal maintained for at least 20 passages | [43] |
Human foreskin fibroblast feeders | hESC (derived lines HS181, HS207) | Self-renewal maintained for over 40 weeks | [44] |
hMSC feeders | CD34+ UC-HSPC | ~2–7 fold Increase LTC-IC population | [83] |
Human osteoblast feeders | CD34+ BM-HSPC | 8 fold increase in CD34+ population | [36] |
BM stromal feeders | CD34+ BM-HSPC | Supported HSPC culture for 5 weeks and maintained LTC-IC populations | [84] |
Human prostate CAF | PC3 | Enriched CD44hi/CD24lo CSC population | [85] |
Primary colonic human myofibroblasts | Primary human colon carcinoma | CSC differentiation prevented in 2D culture | [86] |
BM-hMSC | SUM159, SUM149, MCF-7 | Three-fold increase in cancer stem cell population to 14% of total population | [87] |
| |||
ECM Coatings/Gels | |||
| |||
Matrigel | hESC (H1, H7, H9, H14) | Sustained culture for up to 21 passages in defined media | [45] |
Combination of laminin, collagen IV, fibronectin, vitronectin | hESC (H1, H9; derived WA15, WA16) | Sustained culture for up to 7 months in defined media | [45] |
Matrigel | hESC (H1, H7, H9, H14) | Undifferentiated cells maintained for over 6 months with conditioned media | [18] |
Laminin | hESC (H1, H7, H9, H14) | Undifferentiated cells maintained for at least 7 passages with conditioned media | [18] |
Collagen IV | hESC (H1, H7, H9) | Some undifferentiated colonies present after 6passages with conditioned media | [18] |
| |||
Culture Substrate | Cell Type | Highlighted Results | Reference |
| |||
Fibronectin | hESC (H1, H7, H9) | Some undifferentiated colonies present after 6 passages with conditioned media | [18] |
Vitronectin | hESC (HUES1, HES2, HESC-NL3) | Sustained culture for up to 12 weeks in defined media | [21] |
Laminin | hESC (HUES1, HES2, HESC-NL3) | hESC growth not supported in defined media | [21] |
Fibronectin | hESC (HUES1, HES2, HESC-NL3) | hESC growth not supported in defined media | [21] |
Collagen IV | hESC (HUES1, HES2, HESC-NL3) | hESC growth not supported in defined media | [21] |
Fibronectin | hESC (I3, I6, H9) | Sustained undifferentiated hESCs for up to 38 passages with growth factor addition | [46] |
Chitosan/Alginate scaffold | hESC (BG01V) | Maintained for 21 days in culture in defined media | [88] |
Gelatin | hESC (I3, I6, H9) | 70% more differentiation after 6 days compared to fibronectin coating | [46] |
Laminin-511 | hESC (HS420, HS207, HS401), iPSC (BJ#12, LDS1.4) | Self-renewal maintained for over 4 months | [47] |
Laminin-521 + E-Cadherin | hESC (H1, HS401) | Efficient derivation and self-renewal of hESCs for over 20 passages with high cloning efficacy | [48] |
A variety of ECMs and sera coatings | hESC (HS237, HS293, HS360, HS401, Regea 06/105, HS237) | All substrates tested were significantly inferrior to Matrigel in maintaining hESC cultures | [50] |
Vitronectin coated TCPS | hESC (H9, H14), IPSC (iPS(IMR-90)-3, iPS(IMR-90)-4, iPS(foreskin)-2) | Maintained for 9 passages | [89] |
Vitronectin coated UVPS | iPSC | Sustained culture for up to 2 months | [49] |
Puramatrix™ Synthetic ECM + hMSC feeders | CD34+ BM-HSPC | Increased LTC-IC population | [90] |
| |||
Culture Substrate | Cell Type | Highlighted Results | Reference |
| |||
Fibrin gel + hMSC feeders | CD34+ UC-HSPC | More efficient CD34+ population enhancement than collagen I or polymer scaffolds | [91] |
Fibronectin conjugated PET film | CD34+ UC-HSPC | 19 fold increase in CD34+ cells | [92] |
Fibronectin adsorbed PET fibers | CD34+ UC-HSPC | 2 fold increase in CD34+ cells | [92] |
Fibronectin conjugated PET fibers | CD34+ UC-HSPC | 100 fold increase in CD34+ cells, with 45 foldincrease in LTC-IC population | [92] |
Collagen conjugated PET fibers | CD34+ UC-HSPC | 73 fold increase in CD34+ cells with 4 fold increase in LTC-IC population | [92] |
Fibrin Gel | A2780, HepG2, Primary Patient | Formed spheroids indicating enrichment of CSC | [93] |
Laminin coated TCPS | Primary Brain Tumors (derived G144, G166, G179) | Supported cell lines consisting mostly of glioma neural stem cells | [61] |
Collagen Scaffold | MCF-7 | Increasedangiogenic GF and MMP expression and enhanced CD44+/CD24− population | [94] |
Fibronectin coated PDMS | SUM159, MDA-MB-468 | No enrichment of CSCs, not affected by stiffness | [95] |
BSA coated PDMS | SUM159, MDA-MB-468 | More than doubled CSC population, not affected by stiffness | [95] |
Collagen coated PDMS | SUM159, MDA-MB-468 | No enrichment of CSCs, not affected by stiffness | [95] |
Laminin-511 coating | CD44+/CD24− Src-transformed MCF10A, SUM 1315 | Increased adhesion and enhanced TAZ gene expression | [62] |
FBS coated PCL fibers | MCF-7, T47D, SK-BR-3 | Three-fold increase in proportion of ALDH+ cells, increased mammosphere formation | [96] |
| |||
Culture Substrate | Cell Type | Highlighted Results | Reference |
| |||
Peptide Modified Surfaces | |||
| |||
BSP-PAS | hESC (H1, H7) | Undifferentiated cells maintained for over 16 passages in defined media | [68] |
VN-PAS | hESC (H1, H7) | Undifferentiated cells maintained for over 16passages in defined media | [68] |
sFN-PAS | hESC (H1, H7) | No cell adhesion observed | [68] |
lFN-PAS | hESC (H1, H7) | No cell adhesion observed | [68] |
LM-PAS | hESC (H1, H7) | No cell adhesion observed | [68] |
Peptide SAM microarray | hESC (H1, H9) | Cell adhesion observed with integrin binding peptides, but these peptides did not effectively maintain hESCs. Heparin-binding peptide sequences bound cells and allowed for self-renewal. | [69] |
GKKQRFRHRNRKG SAM | hESC (H1, H7, H9, H14), iPSC (IMR-90, DF19-9 7T) | Heparin binding peptide SAM sustained undifferentiated cells for 2–3 months | [69] |
Amine functional TCPS modified with CRGD | hESC (H9, H14) | Continuously cultured and remained undifferentiated for at least 10 passages. Superior cell adhesion compared to linear RGDS sequence. | [66] |
VN-pDA-PS | hESC (H9), iPSC | Sustained culture for over 3 months in defined media | [97] |
FN patterned PEGDA | CD34+ UC-HSPC | Enhanced adhesion, no effect on stemness | [98] |
OPN patterned PEGDA | CD34+ UC-HSPC | Enhanced adhesion, no effect on stemness | [98] |
RGD patterned PEGDA | CD34+ UC-HSPC | Enhanced adhesion, no effect on stemness | [98] |
RGDSK-PEG-Acrylate hydrogel + hMSC feeders | CD34+ UC-HSPC | Increased expansion, CD34+ expression, and early progenitor cell population | [71] |
RGD conjugated PEGDA | 4T1, MCF-7 | Decreased CD44hi/CD24lo sub-population of breast cancer cells | [70] |
| |||
Culture Substrate | Cell Type | Highlighted Results | Reference |
| |||
FHBP conjugated PEGDA | 4T1, MCF-7 | Enriched CD44hi/CD24lo sub-population of breast cancer cells | [70] |
CD44BP conjugated PEGDA | 4T1, MCF-7 | Decreased CD44hi/CD24lo sub-population of breast cancer cells | [70] |
| |||
Fully Synthetic Polymer Hydrogels | |||
| |||
PMEDSAH | hESC (BG01, H9) | Pluripotency maintained for over 20 passages, up to 10 passages in defined media | [74] |
APMAAm | hESC (H1s, H9-hOct4-pGZs) | Sustained culture for over 20 passages in defined media | [78] |
PMVE-alt-MA | hESC (HUES1, HUES9), iPSC | Increased endogenous ECM production, maintained pluripotency for five passages | [79] |
The strategies outlined in the table have been used to create microenvironments, which expand stem cell populations while preserving their phenotype. Comparing the strategies of culturing different types of stem cells reveals common elements, indicating advances in culturing one type of stem cell may have implications in other stem cell fields as well. However, it should be noted that the use of different growth factors, medias, or culture techniques may contribute to some of the observed results. However, the purpose of this table is to highlight the different substrates, and the similarity between different stem cell types, used in culturing of a variety of stem cells.
Abbreviations: MEF=mouse embryonic fibroblast, ICM=inner cell mass, hESC=human embryonic stem cell, iPSC=induced pluripotent stem cell, UC=umbilical cord, HSPC= hematopoietic stem progenitor cell, PMVEC=porcine microvascular endothelial cell, FS=fetal skin, FM=fetal muscle, hMSC=human mesenchymal stem cell, BM=bone marrow, LTC-IC=long term culture initiating cells, CAF=cancer associated fibroblast, CSC=cancer stem cell, TCPS=tissue culture polystyrene, PET=polyethylene terephthalate, GF=growth factor, MMP=matrix metalloprotease, ECM=extracellular matrix, PDMS=polydimethylsiloxane, UVPS=ultraviolet-ozone treated polystyrene, BSA=bovine serum albumin, FBS=fetal bovine serum, PCL=polycaprolactone, BSP=bone sialoprotein derived peptide, VN=vitronectin derived peptide, sFN=short fibronectin binding peptide, lFN=long fibronectin binding peptide, LM=laminin derived peptide, PAS=peptide-acrylate surface, OPN=osteopontin, FN=fibronectin, SAM=self-assembled monolayer, pDA=polydopamine, PS=polystyrene, PEG=polyethylene glycol, FHBP=fibronectinheparan binding peptide, CD44BP=CD44 binding peptide, PEGDA=polyethylene glycol diacrylate, PMVE-alt-MA= poly(methyl vinyl ether-alt-maleic anhydride), APMAAm=aminopropylmethacrylamide hydrogel, PMEDSAH=poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide]